S-1: Citius Oncology Files S-1 for $15 Million Capital Raise to Fund LYMPHIR Commercialization Amidst Going Concern Warning

Citius Oncology, Inc. has filed an S-1 registration statement to raise up to $15 million through a public offering of common stock and warrants, aiming to fund the commercialization of its recently FDA-approved oncology drug LYMPHIR, while facing substantial doubt about its ability to continue as a going concern.

Summary

• Citius Oncology, Inc. is a biopharmaceutical company focused on developing and commercializing innovative targeted oncology therapies, with its lead product candidate, LYMPHIR, approved by the FDA in August 2024 for persistent or recurrent CTCL.
• The company is offering up to $15 million of common stock and accompanying warrants, and pre-funded warrants in lieu of common stock, with an additional $750,000 of common stock underlying placement agent warrants.
• Net proceeds from the offering are primarily intended for the commercialization of LYMPHIR, including milestone, royalty, and other payments under current license agreements, as well as for working capital and general corporate purposes.
• The company has a history of net losses, with a net loss of $14,394,757 for the six months ended March 31, 2025, and an accumulated deficit of $53,673,344 as of the same date.
• As of March 31, 2025, Citius Oncology had only $112 in cash and a negative working capital of approximately $31.7 million, leading its independent registered public accounting firm to include an explanatory paragraph stating substantial doubt about its ability to continue as a going concern.
• The company is heavily dependent on Citius Pharma for funding and operational functions through a shared services agreement, and owes Citius Pharma $3,800,111 under a promissory note repayable upon a financing of at least $10 million.
• Significant milestone payments are due to licensors: $22.5 million to Dr. Reddys (partially deferred) and a structured payment plan to Eisai totaling $9,433,210 by December 15, 2025, for LYMPHIR approval and incurred costs.
• The estimated addressable U.S. market for LYMPHIR is believed to exceed $400 million, with the company planning to establish a small, targeted oncology sales force and leverage its inclusion in NCCN guidelines.
• The company recently regained compliance with Nasdaq's minimum bid price rule on June 26, 2025, after its stock closed below $1.00 per share for 30 consecutive business days.

Sentiment

Score: 3

Explanation: The company faces significant financial distress, evidenced by a 'going concern' warning, substantial accumulated deficits, and minimal cash reserves. While FDA approval for LYMPHIR is a positive, the immediate and substantial funding requirements, coupled with reliance on a single approved product and related party transactions, indicate a high-risk investment. The preliminary positive clinical trial results for a new indication are encouraging but are early-stage and do not offset the immediate financial challenges.

Positives

• LYMPHIR, the company's lead product candidate for persistent or recurrent CTCL, received FDA approval in August 2024.
• The company estimates an attractive and growing market for LYMPHIR, projected to exceed $400 million, which is currently underserved by existing treatments.
• LYMPHIR has been included in the National Comprehensive Cancer Network (NCCN) guidelines and compendia with a Category 2A recommendation, which is expected to assist in obtaining coverage and reimbursement from the Centers for Medicare and Medicaid Services (CMS).
• Preliminary results from a Phase 1 clinical trial of Pembrolizumab (KEYTRUDA) and LYMPHIR in recurrent solid tumors showed a 27% overall response rate (4/15) and a 33% clinical benefit rate (5/15) among evaluable patients, with a median progression-free survival of 57 weeks for those achieving clinical benefit.
• The combination regimen in the solid tumor trial was generally well tolerated, with no significant immune-related adverse events observed and only one case of dose-limiting toxicity reported at the highest dose level.
• The company successfully regained compliance with Nasdaq's minimum bid price requirement on June 26, 2025.

Negatives

• The company's independent registered public accounting firm's report includes an explanatory paragraph stating substantial doubt about its ability to continue as a going concern.
• Citius Oncology has a history of net losses, incurring $7,735,552 for the quarter ended March 31, 2025, and $14,394,757 for the six months ended March 31, 2025.
• As of March 31, 2025, the company had only $112 in cash and cash equivalents and a negative working capital of approximately $31.7 million.
• The company has significant outstanding liabilities, including $16.4 million to third-party suppliers and manufacturers, and an aggregate of $28.4 million in due and outstanding amounts under its license agreements as of March 31, 2025.
• A $22.5 million milestone payment to Dr. Reddys remains due as of March 31, 2025, with a partial deferral agreed upon pending further discussions.
• The company is obligated to pay Eisai $2,535,318 by July 15, 2025, followed by four monthly payments of $2,350,000 and a final payment of $2,197,892 by December 15, 2025, plus 2% annual interest on original due dates.
• The company is entirely dependent on the successful commercial launch of LYMPHIR to generate revenue for the foreseeable future, with the launch not expected until the second half of 2025.
• The company has limited operating history and unproven commercialization capabilities, relying on a third-party organization for sales and marketing.
• The company is a controlled company, with Citius Pharma owning approximately 92.3% of its outstanding common stock as of June 30, 2025, which could lead to conflicts of interest and differing priorities from public stockholders.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to historical operating losses and expected future negative cash flows.
• Requirement for substantial additional funding beyond the current offering to support operations and commercialization of LYMPHIR, which may not be available on acceptable terms or at all.
• Heavy dependence on the planned launch and commercial success of LYMPHIR, as it is the only approved product.
• Obligation to make significant milestone and other payments to licensors (Eisai and Dr. Reddys), which could adversely affect profitability and require additional financing.
• Risk of material breach or default under license agreements, including failure to make timely payments, which could lead to termination of licensing rights and materially harm the business.
• Exclusive reliance on third parties for formulation and manufacturing of product candidates, with risks of delays or loss of support if contractual obligations, including timely payment, are not met.
• Uncertainty regarding market acceptance of LYMPHIR among physicians, patients, healthcare payers, or the medical community, which is critical for revenue generation.
• Challenges in establishing effective marketing, sales, and distribution capabilities for LYMPHIR, as the company has limited direct experience in commercial activities.
• Intense competition in the pharmaceutical and medical products industries from companies with substantially greater resources and experience.
• Potential for diminished product revenues if LYMPHIR sells for inadequate prices or if patients cannot obtain adequate reimbursement levels from healthcare payers.
• Adverse impact from healthcare reform measures, including potential price controls, reduced reimbursement rates, and increased governmental scrutiny over drug pricing.
• Risks associated with the ongoing exploration of strategic alternatives, which may not result in completed transactions or may negatively affect stock price.
• Volatility in the market price of the common stock due to various factors, including financial condition, operating results, regulatory decisions, and competitive developments.
• Potential for significant dilution of ownership interests due to future issuance of additional shares of common stock or securities convertible into common stock.
• Risk of delisting from Nasdaq if compliance with continued listing requirements, such as the minimum bid price rule, is not maintained in the future.
• Lack of an established trading market for the Warrants and Pre-Funded Warrants, limiting their liquidity.
• Potential conflicts of interest arising from the relationship with Citius Pharma, which controls the company and provides many corporate functions.
• Dependence on Citius Pharma for operational functions, systems, and infrastructure, which would be difficult and costly to replace if Citius Pharma ceases providing them.
• Uncertainty regarding the predictive nature of pre-clinical and completed clinical trial results for future studies or product candidates, potentially leading to delays or abandonment of development.

Future Outlook

The company expects to incur losses for the foreseeable future as it continues commercialization efforts for LYMPHIR and advances research for other indications. Its continued operations beyond August 2025 are dependent on successfully launching LYMPHIR to generate substantial revenue and/or raising additional capital through equity/debt financings, strategic relationships, or out-licensing. The company is actively evaluating strategic alternatives to maximize shareholder value, including partnerships, joint ventures, mergers, acquisitions, or licensing transactions.

Management Comments

• Leonard Mazur, Chief Executive Officer and Chairman, has extensive sales, marketing, and business development experience in the pharmaceutical industry.
• Jaime Bartushak, Chief Financial Officer and Treasurer, is an experienced finance professional for early-stage pharmaceutical companies with over 20 years of corporate finance, business development, restructuring, and strategic planning experience.
• Dr. Myron Czuczman, Chief Medical Officer, has significant experience in lymphoma/CLL and translational research, having previously served as Vice President, Global Clinical Research and Development at Celgene Corporation.
• Myron Holubiak, Secretary and Director, has extensive experience in managing and advising large and emerging pharmaceutical and life sciences companies, including serving as President of Roche Laboratories, Inc.

Industry Context

Citius Oncology operates within the highly competitive biopharmaceutical and oncology industries, characterized by costly R&D, sales, and marketing efforts. Its lead product, LYMPHIR, targets Cutaneous T-cell Lymphoma (CTCL), a rare form of non-Hodgkin lymphoma. The market for CTCL treatments is competitive, with several approved targeted therapeutics such as Mogamulizumab (Poteligeo), Brentuximab vedotin (Adcetris), Romidepsin (Istodax), and Vorinostat (Zolinza. The company believes there is an unmet medical need and an opportunity for LYMPHIR, especially given its differentiated mechanism of action and promising preliminary results in immuno-oncology combination therapy trials.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• The company is not involved in any litigation that it believes could have a material adverse effect on its financial position or results of operations. There is no action, suit, proceeding, inquiry, or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the company's executive officers, threatened against or affecting the company or its officers or directors in their capacities as such.

Related Party Transactions

• Citius Pharma, the parent company, continues to fund Citius Oncology's operations and provides management and scientific services under an Amended and Restated Shared Services Agreement (A&R Shared Services Agreement).
• Under the A&R Shared Services Agreement, Citius Pharma charges Citius Oncology an aggregate quarterly fee of approximately $940,000 and is reimbursed for all reasonable out-of-pocket costs and expenses.
• As of March 31, 2025, Citius Oncology owed Citius Pharma $4,941,664 in the 'due to related party' account.
• Citius Pharma made a capital contribution of $33,180,961 to Citius Oncology by reclassifying intercompany receivables to additional paid-in capital.
• Citius Pharma advanced $3,800,111 to Citius Oncology under an unsecured, non-interest-bearing promissory note dated August 16, 2024, repayable in full upon a financing of at least $10 million by Citius Oncology.
• Except for one director, all of Citius Oncology's directors, executive officers, and employees also serve as directors and employees of Citius Pharma, creating potential conflicts of interest.

Stakeholder Impact

• **Shareholders:** Face significant dilution from the current offering and potential future equity financings. Existing shareholders may experience a decrease in the market price of their shares due to volatility and the 'going concern' warning. The controlled company status by Citius Pharma may limit the influence of minority shareholders.
• **Employees:** The company has no direct employees, relying on Citius Pharma's personnel through a shared services agreement. This arrangement could pose risks if Citius Pharma ceases providing services or if Citius Oncology needs to build its own infrastructure.
• **Customers/Patients:** The successful commercialization of LYMPHIR could provide a new treatment option for patients with persistent or recurrent CTCL. However, market acceptance and reimbursement challenges could impact product availability and affordability.
• **Suppliers/Creditors:** The company has substantial outstanding liabilities to third-party suppliers and manufacturers ($16.4 million) and licensors ($28.4 million), raising concerns about timely payments and potential disruptions to supply if funding is not secured.
• **Licensors (Eisai, Dr. Reddys):** The company has significant milestone and royalty payment obligations. Failure to meet these payments could lead to termination of license agreements, impacting the company's ability to commercialize LYMPHIR.

Next Steps

• Commercial launch of LYMPHIR in the U.S. is expected in the second half of 2025.
• The company plans to continue raising additional capital through equity and/or debt financings, strategic relationships, or out-licensing of product candidates.
• Ongoing evaluation of strategic alternatives, including partnerships, joint ventures, mergers, acquisitions, or licensing transactions, to maximize shareholder value.
• Continued development of LYMPHIR for other possible indications, with two investigator-initiated immuno-oncology trials currently enrolling patients.
• Repayment of milestone payments and unpaid invoices to Eisai according to the agreed-upon schedule, with the first payment due July 15, 2025, and the final by December 15, 2025.
• Repayment of the $3,800,111 promissory note to Citius Pharma if the gross proceeds from the current offering equal or exceed $10 million.
• Establishment of a small, targeted oncology sales force and continued marketing efforts for LYMPHIR.

Key Dates

Recommendation

Keywords

Citius Oncology, LYMPHIR, CTCL, Cutaneous T-cell Lymphoma, Oncology, Biopharmaceutical, FDA Approval, SEC Filing, S-1 Registration, Capital Raise, Warrants, Pre-Funded Warrants, Nasdaq, Going Concern, Clinical Trials, Immunotherapy, Rare Disease, Drug Commercialization, Financial Health, Risk Factors